Boston firm, Alexion acquires Achillion for $930 million
Achillion Pharmaceuticals Inc. has been purchased by Alexion Pharmaceuticals Inc. of Boston for $930 million, or $6.30 a share, pending approval by Achillion shareholders and regulators. Achillion shareholders will also get an extra dollar a share if the FDA approves Achillion’s Danicopan (for a rare blood disease) and another dollar if a drug in development